A phase 1b, multicenter, open-label, dose-finding study of eribulin in combination with carboplatin in advanced solid tumors and non-small cell lung cancer

No abstract is available for this paper.

• Publication year

  2019

• Venue

  Cancer Chemotherapy and Pharmacology

• Publication date

  2019-06-12

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00280-019-03877-4PMID 31190276
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician’s choice in patients with advanced non-small cell lung cancer

  2017cited by this paper
• Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

  2017cited by this paper
• Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

  2016cited by this paper
• Eribulin Mesylate: Mechanism of Action of a Unique Microtubule-Targeting Agent

  2015cited by this paper
• Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

  2015cited by this paper
• An open-label, multicenter, randomized phase Ib/II study of eribulin mesylate administered in combination with pemetrexed versus pemetrexed alone as second-line therapy in patients with advanced nonsquamous non-small-cell lung cancer.

  2015cited by this paper
• 470PA PHASE I STUDY OF ERIBULIN AND GEMCITABINE IN PATIENTS WITH AVANCED SOLID TUMOURS. A STUDY OF THE PRINCESS MARGARET PHASE II CONSORTIUM.

  2014cited by this paper
• Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer.

  2013cited by this paper
• Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy.

  2012cited by this paper
• A Phase II Study of Halichondrin B Analog Eribulin Mesylate (E7389) in Patients with Advanced Non-small Cell Lung Cancer Previously Treated with a Taxane: A California Cancer Consortium Trial

  2012cited by this paper
• National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology

  2012cited by this paper
• Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy.

  2012cited by this paper
• A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer.

  2012cited by this paper
• Eribulin mesylate in patients with refractory cancers: a Phase I study

  2011cited by this paper
• Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

  2011cited by this paper
• National Comprehensive Cancer Network (NCCN) Head and Neck Cancers NCCN Clinical Practice Guidelines in Oncology . 2010.

  2011cited by this paper
• ECOG 5805: A phase II study of eribulin mesylate (E7389) in patients (pts) with metastatic castration-resistant prostate cancer (CRPC).

  2010cited by this paper
• Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability.

  2010cited by this paper
• A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies

  2009cited by this paper
• Paclitaxel, Estramustine and Carboplatin Combination Chemotherapy after Initial Docetaxel-Based Chemotherapy in Castration-Resistant Prostate Cancer

  2009cited by this paper
• Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial.

  2009cited by this paper
• Response to docetaxel/carboplatin‐based chemotherapy as first‐ and second‐line therapy in patients with metastatic hormone‐refractory prostate cancer

  2008cited by this paper
• A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone‐refractory prostate cancer who are refractory to docetaxel

  2008cited by this paper
• Randomized Phase II study comparing paclitaxel and carboplatin versus mitoxantrone in patients with hormone-refractory prostate cancer.

  2006cited by this paper
• A phase I pharmacokinetic and target validation study of the novel anti-tubulin agent E7389: A California Cancer Consortium trial

  2005cited by this paper
• Sequence effect of docetaxel and carboplatin on toxicity, tumor response and pharmacokinetics in non-small-cell lung cancer patients: a phase I study of two sequences

  2005cited by this paper
• Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

  2002cited by this paper
• Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial.

  2001cited by this paper
• Sequences of taxol and cisplatin: a phase I and pharmacologic study.

  1991cited by this paper
• Clinical Pharmacokinetics of Carboplatin

  1988cited by this paper

• An intracerebral microdialysis study to determine the neuropharmacokinetics of eribulin in patients with metastatic or primary brain tumors

  2024cites this paper
• Application of marine natural products in drug research.

  2021cites this paper
• Multifarious targets beyond microtubules-role of eribulin in cancer therapy.

  2021cites this paper